'; setTimeout(function() { var videoIframe519870570538872470Actual = document.getElementById("video-iframe-519870570538872470").contentDocument; videoIframe519870570538872470Actual.open().write(videoIframe519870570538872470Content); videoIframe519870570538872470Actual.close(); }, 500);

The Nanosense team was formed from a few self-advertising, entrepreneurs provided to us in a list by the Center for Advancing Innovation. Although we lacked proximity to each other, we each shared a common dedication to excel. This became very important when developing new ideas and maintaining team momentum to complete all deliverables. Simply put, motivated people don’t need to directly hold hands to traverse new paths together. That list created by CAI established a melting-pot background, startup experience and academic training that gave our team diverse strength and professional companionship which, in turn enhanced our ability re-envision Invention 4. 

We had big ideas about this sensor technology but initially lacked clarity on what specific cancer problems we could apply it to. There is no estimation for the time we spent in finding real targets to focus on. Meanwhile, the CAI webinars helped us to understand how to compare strengths, weaknesses, opportunities and threats for each target. So far, we have made many journeys and pivots but finally transformed our golden technology into a gilded arrow with golden purpose: to create a new cancer diagnostic test that is needed by people infected with Human Papillomavirus. Team dedication was more important than proximity to find the real value in Invention 4.

Currently, HPV+ women have no companion diagnostics to the traditional Pap smear or cervical biopsy which can fail to detect HPV cancer at high rates. Further, HPV+ men have even fewer molecular diagnostic options that provide cancer-definitive answers. Our conceptual arrow can detect HPV cancer, monitor HPV cancer treatment efficacy, and save lives with profitable margins.

When it comes to molecular diagnostics in HPV, centralized testing hubs command the governance, standards, and rich resources that enable most testing in the US. This hub of plenty is now at $360 million and is growing annually at rates of 10% or better. Our extensive research uncovered many natural barriers that severely limit current hub technologies to detect HPV cancer biomarkers. We are excited to point out that Invention 4 can overcome these natural barriers and thus makes a fantastic companion diagnostic with specific advantages that are difficult to reproduce. We have no apologies for the identified competitors as we make HPV cancer diagnostics better than ever before.

Our new HPV focus made changes to our current business plan. When we apply for a license from the NIH, we intend to develop this technology for cancer diagnostics related to viral infections. We want to initially work with the inventor, Dr. Javed Kahn at NCI, to quickly prototype the technology for miniaturized optimization. Over the next months, we will reorganize our team and reinvent with new talent that will aid our success for the challenges ahead. Specifically, we must retool for several HPV preclinical studies to optimize sensitivity, microchip optimization, manufacturing, and  smartphone software development. Our primary goal is to initiate a milestone which is to incorporate as an LLC, this month. -Eric Hamlett, Nanosense
0 Comments



Leave a Reply.